![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).
Lead Product(s): VMB-100
Therapeutic Area: Urology Product Name: VMB-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Touchlight
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.
Lead Product(s): VMB-100
Therapeutic Area: Urology Product Name: VMB-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Touchlight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2022
Details:
VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress Urinary Incontinence.
Lead Product(s): VMB-100
Therapeutic Area: Urology Product Name: VMB-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.
Lead Product(s): RNA based therapies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Financing July 15, 2020